​​​
  1. Glenmark launches digital dose inhaler for asthma patients

Glenmark launches digital dose inhaler for asthma patients

Glenmark Pharmaceuticals today launched 'Digihaler', the country's first digital dose inhaler (DDI), for asthma and chronic obstructive pulmonary disease (COPD) patients.

By: | New Delhi | Published: May 25, 2016 6:49 PM
digihaler, digital dose inhaler, asthma patients, dose for asthma patients, asthma problems, digital inhaler, Glenmark Glenmark Pharmaceuticals today launched ‘Digihaler’, the country’s first digital dose inhaler (DDI), for asthma and chronic obstructive pulmonary disease (COPD) patients. (Reuters)

Glenmark Pharmaceuticals today launched ‘Digihaler’, the country’s first digital dose inhaler (DDI), for asthma and chronic obstructive pulmonary disease (COPD) patients.

“This next-gen inhaler provides accurate digital dose counter along with low dose warning indicator to enable Asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy,” the Mumbai-based firm said in a statement.

Currently, there are about 35 million asthmatics in India. As per WHO estimates in 2007, there were 300 million people suffering from asthma globally, and it is expected that the figure could increase by further 100 million by 2025.

There have been 2,50,000 deaths per year globally and 57,500 deaths annually in India.

“The device (Digihaler) will enable the patients to track the number of doses that have been consumed and prominently placed indicator provides a low dose warning which is beneficial to patients. This will further enable the doctors to determine patient’s adherence to the prescribed therapy regime,” Glenmark Pharmaceuticals President and Head of India Formulations and Africa Region Sujesh Vasudevan said.

Glenmark shares today ended at Rs 857 apiece on the BSE, down 0.20 per cent from its previous close.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top